Inventiva's Stock Climbs 6.27% Mid-Day After Target Upgrade
The stock of Dijon-based biopharmaceutical company Inventiva surged by 6.27% to 6.10 euros this Wednesday, January 28, at midday. The increase is part of a positive trend with a rise of 18.45% over the last week and nearly 97% over three months. The biotech, specializing in the treatment of NASH with oral therapies, has seen renewed interest from analysts in a post-major fundraising context completed at the end of 2025.
Analyst Endorsements and Financial Projections
This Wednesday, Jefferies maintained its buy recommendation and raised the price target from 3 EUR to 7.50 EUR. This new target, which is 23% above the current price, reflects an attractive appreciation potential according to the financial intermediary. The bank joins Barclays, which recently started covering the stock as overweight with a target price of 18 USD for the American ADR. These positive recommendations come after a $172.5 million fundraising in November 2025 on the Nasdaq, aimed at funding the continuation of the pivotal Phase III clinical trial of lanifibranor against NASH. The company now has enhanced cash reserves enabling it to fund its operations until the first quarter of 2027, which could extend to the third quarter of 2027 if all warrants of Tranche 3 are exercised, representing an additional potential revenue of 116 million euros. The main results of this strategic NATiV3 study are expected in the second half of 2026, a crucial deadline for the commercial future of the drug candidate. Guggenheim also retains its buy recommendation with a target set at 11 euros, representing an upward potential of 80% compared to the current quote.
Technical Analysis and Market Behavior
Technically, the stock's trajectory reflects a sharp acceleration in recent weeks. The RSI indicator has reached 72, crossing the threshold of 70 which traditionally marks an overbought zone, indicating a very marked bullish movement that could lead to a pause or consolidation in the short term. However, the breach of the resistance at 5.98 euros validates the strength of the current trend. The price is now significantly above its moving averages: the MM20 is at 4.84 euros, the MM50 at 4.12 euros, and the MM200 at 3.61 euros. This configuration indicates a well-established positive momentum, supported by a MACD whose histogram remains in positive territory at 0.08. The negative beta of -0.30 indicates a relative decorrelation with the market as a whole. The monthly volatility of 21.24% illustrates the speculative nature of the case, typical of the biotechnology sector where clinical catalysts remain crucial. The market capitalization now exceeds one billion euros, placing Inventiva among the select circle of European biotechs of this size.
